ANI Pharmaceuticals, Inc. (ANIP)
Price:
90.12 USD
( + 0.41 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Cronos Group Inc.
VALUE SCORE:
8
2nd position
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
The best
Lantheus Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
NEWS

ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-11 10:31:30While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 15:56:48ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
zacks.com
2025-08-08 09:00:20ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
globenewswire.com
2025-08-08 06:50:00BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
globenewswire.com
2025-08-01 06:50:00PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
zacks.com
2025-07-29 11:05:41ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
globenewswire.com
2025-07-23 06:50:00Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
zacks.com
2025-07-14 13:11:12ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
globenewswire.com
2025-07-02 06:50:00PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA.

ANI Pharmaceuticals Announces Presentation of New Preclinical Data
globenewswire.com
2025-06-12 07:00:00The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
globenewswire.com
2025-05-27 16:30:00PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
globenewswire.com
2025-05-22 06:50:00Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for the treatment of acute gout flares.

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
globenewswire.com
2025-05-12 18:30:00PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
zacks.com
2025-05-12 13:50:46ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript
seekingalpha.com
2025-05-09 11:44:46ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
zacks.com
2025-05-09 10:46:24Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
No data to display

ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-11 10:31:30While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 15:56:48ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
zacks.com
2025-08-08 09:00:20ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
globenewswire.com
2025-08-08 06:50:00BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
globenewswire.com
2025-08-01 06:50:00PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
zacks.com
2025-07-29 11:05:41ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
globenewswire.com
2025-07-23 06:50:00Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
zacks.com
2025-07-14 13:11:12ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
globenewswire.com
2025-07-02 06:50:00PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA.

ANI Pharmaceuticals Announces Presentation of New Preclinical Data
globenewswire.com
2025-06-12 07:00:00The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
globenewswire.com
2025-05-27 16:30:00PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
globenewswire.com
2025-05-22 06:50:00Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for the treatment of acute gout flares.

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
globenewswire.com
2025-05-12 18:30:00PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
zacks.com
2025-05-12 13:50:46ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript
seekingalpha.com
2025-05-09 11:44:46ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
zacks.com
2025-05-09 10:46:24Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.